Lensar (LNSR) Liabilities and Shareholders Equity (2019 - 2026)
Lensar (LNSR) posted quarterly Liabilities and Shareholders Equity of $66.2 million for Q1 2026, down 9.23% year-over-year from $73.0 million in Q1 2025, and down 7.29% quarter-over-quarter from $71.4 million in Q4 2025.
Lensar (LNSR) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Lensar (LNSR) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $66.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 9.23% year-over-year to $66.2 million; the TTM figure through Mar 2026 stood at $278.3 million (up 5.93% YoY), while the FY2025 annual figure was $71.4 million, up 7.74% from the prior year.
- Liabilities and Shareholders Equity declined to $66.2 million in Q1 2026 per LNSR's latest filing, from $71.4 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $73.0 million in Q1 2025 and bottomed at $52.0 million in Q1 2023.
- Historically, Liabilities and Shareholders Equity has averaged $64.7 million across 5 years, with a median of $66.2 million in 2026.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slipped 19.53% — and 2023, when it rose 29.29%.
- Lensar's Liabilities and Shareholders Equity stood at $55.8 million in 2022, then advanced by 24.61% to $69.6 million in 2023, then decreased by 4.73% to $66.3 million in 2024, then climbed by 7.74% to $71.4 million in 2025, then retreated by 7.29% to $66.2 million in 2026.
- Business Quant data shows LNSR's Liabilities and Shareholders Equity at $66.2 million in Q1 2026, $71.4 million in Q4 2025, and $70.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 47.93 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 45.22 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 13.87 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 6.46 Bn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 37.25 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 31.04 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 10.74 Bn |
| 10 | Lensar | 103.79 Mn | 90.22 Mn | 9.78 Mn | 69.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 69.56 Mn |
| Mar 31, 2026 | 66.22 Mn |
| Dec 31, 2025 | 71.43 Mn |
| Sep 30, 2025 | 70.20 Mn |
| Jun 30, 2025 | 70.41 Mn |
| Mar 31, 2025 | 72.96 Mn |
| Dec 31, 2024 | 66.30 Mn |
| Sep 30, 2024 | 62.02 Mn |
| Jun 30, 2024 | 61.41 Mn |
| Mar 31, 2024 | 66.13 Mn |
| Dec 31, 2023 | 69.59 Mn |
| Sep 30, 2023 | 70.85 Mn |
| Jun 30, 2023 | 71.20 Mn |
| Mar 31, 2023 | 51.96 Mn |
| Dec 31, 2022 | 55.84 Mn |
| Sep 30, 2022 | 54.80 Mn |
| Jun 30, 2022 | 58.70 Mn |
| Mar 31, 2022 | 60.30 Mn |
| Dec 31, 2021 | 66.47 Mn |
| Sep 30, 2021 | 68.10 Mn |